Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Abeona Therapeutics Inc. (Nasdaq: ABEO), a Cleveland-based biotech company, announced Monday, May 12, that it has entered an ...

The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) for use in ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S.